An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy

Trial Profile

An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Fulvestrant (Primary) ; Fulvestrant (Primary)
  • Indications Early breast cancer
  • Focus Adverse reactions
  • Sponsors Atossa Genetics
  • Most Recent Events

    • 12 Apr 2018 Planned End Date changed from 1 Sep 2017 to 1 Dec 2018.
    • 12 Apr 2018 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2018.
    • 09 May 2017 According to an Atossa Genetics media release, the Institutional Review Board associated with Montefiore Medical Center (Biomedical Research Alliance of New York IRB) has approved this Phase 2 study that was recently transferred to Montefiore.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top